Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow REGN by emailGet an email when REGN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about REGN, unsubscribe in one click. Privacy
📣 What REGN Says Is Next
second half of 2026 · “A second interim analysis as well as the study's final analysis, if necessary, are anticipated in the second half of 2026.”
Company press release, Apr 29, 2026 · SEC filing
Q4 2026 · “FDA submission for cemdisiran planned for Q1 2026 with decision expected by Q4 2026/Q1 2027”
Company press release, Jan 12, 2026 · SEC filing
2H 2026 · “Interim data from Phase 3 lead-in cohort anticipated in 2H 2026”
Company press release, Jan 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full REGN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for REGN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.